AMCP supports a coalition of over 20 health care stakeholders committed to aligning 42 CFR Part 2 (part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.
Press Release: February’s themed issue of the Journal of Managed Care & Specialty Pharmacy (JMCP) examines challenges that managed care pharmacists face in administering oncology therapies, including considerations around patient-reported outcomes and the role of caregivers.
Press Release: The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) is pleased to announce the addition of a new participating organization, Apobiologix.
Press Release: The Academy of Managed Care Pharmacy (AMCP) commends the Food and Drug Administration (FDA) for its release today of draft guidance clarifying how biopharmaceutical companies and population health decision makers can proactively share clinical and economic information on both FDA approved products as well as emerging therapies awaiting FDA approval.
The Partnership to Amend 42 CFR Part 2, a coalition of nearly 30 health care organizations committed to aligning the Substance Abuse and Mental Health Service Administration's (SAMHSA) final rule on Confidentiality of Alcohol and Drug Abuse Patient Records, 42 Code of Federal Regulations Part 2 (Part 2) with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) to allow appropriate access to patient information that is essential for providing whole-person care, issued the following statement in response to the Part 2 final rule.
Press Release: The Academy of Managed Care Pharmacy (AMCP) has released a set of consensus recommendations to allow biopharmaceutical companies to proactively share clinical and economic information with population health decision makers on emerging therapies in advance of Food and Drug Administration (FDA) approval.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments on the notice titled “CMS-10396 Medication Therapy Management Program Improvements” published in the Federal Register on October 31, 2016. Under the notice, the Medicare Part D Medication Therapy Management (MTM) Program Standardized Format (“standardized format”) would be reauthorized in its current format for an additional three years through 2020.
AMCP CEO Blog: Who says Congress can’t get anything done…and with bipartisan support to boot? With impressive speed and purpose, the House and Senate overwhelmingly passed the 21st Century Cures Act in the waning days of the 114th Congress.